基于西斯普拉丁的组合疗法:它们的有效性,重点是针对人参化物同时使用的疗法
Keke Li1, Jiwen Li2, Zhongyu Li1
1Key Laboratory of Biotechnology and Bioresources Utilization, Ministry of Education, Dalian Minzu University, Dalian 116600, China.
Pharmacological research
|April 6, 2024
概括
辛氏化物增强了思普拉丁化疗的抗癌能力,并减少了其副作用. 这种组合疗法对克服药物耐药性和改善患者的治疗结果充满希望.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 自然产品 化学 化学
背景情况:
- 西斯是许多癌症的重要化疗药物,但其有效性受到严重的副作用和耐药性的限制.
- 来自人参的金色化物是具有多种生物活性的生物活性化合物,包括抗癌性质.
研究的目的:
- 审查因子化物增强西斯普拉丁抗癌功效并减轻其毒性的机制.
- 探索将西斯与人参化物结合以改善癌症治疗结果的潜力.
主要方法:
- 关于西斯普拉丁和人参化物联合治疗的临床前和临床研究的文献综述.
- 基于协同效应和降低毒性的分子机制的分析.
主要成果:
- 金色化物增强了西斯普拉丁的DNA破坏作用和癌细胞中亡诱导.
- 同时服用人参化物可降低对脏,肝脏,神经系统和其他器官的西斯普拉丁诱导毒性.
- 银化物可以克服西斯普拉丁耐药机制,从而提高治疗反应.
结论:
- 与西斯普拉丁和人参化物联合治疗提供了一种有前途的策略,以提高癌症治疗疗效和患者安全.
- 建议对协同机制进行进一步的研究,以优化这种联合模式治疗.
相关概念视频
Combined Effects of Drugs: Synergism
3.9K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.9K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
198
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
198
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
160
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
160


